Last $2.03 USD
Change Today -0.25 / -10.96%
Volume 1.9M
OGXI On Other Exchanges
Symbol
Exchange
Munich
NASDAQ CM
As of 8:10 PM 12/19/14 All times are local (Market data is delayed by at least 15 minutes).

oncogenex pharmaceutical inc (OGXI) Snapshot

Open
$2.33
Previous Close
$2.28
Day High
$2.34
Day Low
$1.98
52 Week High
03/11/14 - $14.25
52 Week Low
12/19/14 - $1.98
Market Cap
43.2M
Average Volume 10 Days
363.4K
EPS TTM
$-1.74
Shares Outstanding
21.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ONCOGENEX PHARMACEUTICAL INC (OGXI)

Related News

No related news articles were found.

oncogenex pharmaceutical inc (OGXI) Related Businessweek News

No Related Businessweek News Found

oncogenex pharmaceutical inc (OGXI) Details

OncoGenex Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapies that address treatment resistance in cancer patients. Its lead drug candidate, Custirsen is in Phase III clinical development for the treatment in men with metastatic castrate-resistant prostate cancer, and in patients with advanced, unresectable non-small cell lung cancer. Custirsen is an experimental drug designed to block the production of the protein clusterin, which may play a fundamental role in cancer cell survival and treatment resistance. The company also develops Apatorsen, which is in seven randomized Phase II trials for the treatment of bladder, lung, pancreatic, and prostate cancers. Apatorsen is an investigational drug designed to inhibit the production of heat shock protein (Hsp27), a protein that is elevated in various cancers and that has been shown to promote cancer cell growth and tumor metastasis. In addition, it develops OGX-225 that is in pre-clinical development for the treatment of solid tumors. The company has a collaboration and license agreement with Teva Pharmaceutical Industries Ltd. to develop and commercialize Custirsen. The company is headquartered in Bothell, Washington.

37 Employees
Last Reported Date: 03/11/14

oncogenex pharmaceutical inc (OGXI) Top Compensated Officers

Founder, Chief Executive Officer, President, ...
Total Annual Compensation: $503.7K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $403.1K
Compensation as of Fiscal Year 2013.

oncogenex pharmaceutical inc (OGXI) Key Developments

OncoGenex Pharmaceuticals, Inc. Announces Results from Phase 2 Borealis-1 Trial

On December 19, 2014, OncoGenex Pharmaceuticals, Inc. announced results from the randomized, controlled Phase 2 Borealis-1 trial evaluating low and high dose (600mg and 1,000mg) apatorsen in combination with gemcitabine/cisplatin chemotherapy compared to chemotherapy alone in the treatment of metastatic bladder cancer. Overall trial results indicated that the addition of 600mg apatorsen to standard of care chemotherapy showed a 14% reduction in risk of death (overall survival hazard ratio (HR) = 0.86) and a 17% reduction in progressive disease and death (progression-free survival HR = 0.83) when compared to chemotherapy alone. Over one-third of the patients in the trial had lower performance status, as defined by a Karnofsky score of 80% or less. These patients derived the benefit from 600mg apatorsen in combination with chemotherapy, resulting in a 50% reduction in risk of death (overall survival HR = 0.50) compared to chemotherapy alone. Less benefit was observed in the 1,000mg apatorsen arm due to increased adverse events to a higher rate of discontinuation of both apatorsen and chemotherapy. Apatorsen 600mg was well tolerated in combination with chemotherapy. OncoGenex will be working closely with investigators and regulatory agencies to determine next steps.

OncoGenex Announces Results from the Phase 2 Borealis-1

OncoGenex Pharmaceuticals, Inc. announced results from the randomized, controlled Phase 2 Borealis-1 trial evaluating low and high dose (600mg and 1,000mg) apatorsen in combination with gemcitabine/cisplatin chemotherapy compared to chemotherapy alone in the treatment of metastatic bladder cancer. Overall trial results indicated that the addition of 600mg apatorsen to standard of care chemotherapy showed a 14% reduction in risk of death (overall survival hazard ratio (HR) = 0.86) and a 17% reduction in progressive disease and death (progression-free survival HR = 0.83) when compared to chemotherapy alone. Over one-third of the patients in the trial had lower performance status, as defined by a Karnofsky score of 80% or less. These patients derived great benefit from 600mg apatorsen in combination with chemotherapy, resulting in a 50% reduction in risk of death (overall survival HR = 0.50) compared to chemotherapy alone. Less benefit was observed in the 1000mg apatorsen arm due to increased adverse events to a higher rate of discontinuation of both apatorsen and chemotherapy. Apatorsen 600mg was well tolerated in combination with chemotherapy. Apatorsen is designed to inhibit production of heat shock protein 27 (Hsp27), which increases with cancer treatment as well as with tumor stage and grade. High levels of Hsp27 contribute to cancer cell survival, proliferation and migration and also play a role in dampening a cancer patient's immune function. Borealis-1 enrolled approximately 180 patients with documented metastatic or locally inoperable transitional cell carcinoma (TCC) of the urinary tract who had not previously received chemotherapy for metastatic disease and were not candidates for potentially curative surgery or radiotherapy. Patients were randomized to receive standard chemotherapy (gemcitabine/cisplatin) in combination with apatorsen at two dose levels (600 mg and 1,000 mg) or gemcitabine/cisplatin plus placebo. Patients received up to six cycles of weekly intravenous therapy. Following the discontinuation of a minimum of four cycles of chemotherapy, all patients received weekly apatorsen or placebo maintenance therapy until disease progression or other reason for withdrawal from protocol treatment. The primary endpoint of the trial was overall survival. Secondary endpoints measured disease response as well as safety of each of the two doses of apatorsen.

OncoGenex Pharmaceuticals, Inc. Presents at Stifel Healthcare Conference 2014, Nov-19-2014 10:55 AM

OncoGenex Pharmaceuticals, Inc. Presents at Stifel Healthcare Conference 2014, Nov-19-2014 10:55 AM. Venue: The Palace Hotel, 455 Madison Ave, New York, NY 10022, United States. Speakers: Scott Daniel Cormack, Founder, Chief Executive Officer, President, Treasurer, Secretary and Director.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
OGXI:US $2.03 USD -0.25

OGXI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for OGXI.
View Industry Companies
 

Industry Analysis

OGXI

Industry Average

Valuation OGXI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.4x
Price/Book 1.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ONCOGENEX PHARMACEUTICAL INC, please visit www.oncogenex.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.